Key facts
- This page summarizes Stuart Cobb's Form 3 filing for Neurogene Inc. (NGNE).
- 0 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 26 Dec 2023, 18:05.
Stuart Cobb - 18 Dec 2023 Form 3 Insider Report for Neurogene Inc. (NGNE)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- NGNE
- Reported as of
- 18 Dec 2023
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 26 Dec 2023, 18:05:12 UTC
- Next SEC filing
- 14 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christine Mikail, as attorney-in-fact for Stuart Cobb
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Stuart Cobb filed Form 3 for Neurogene Inc. (NGNE) on 26 Dec 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NGNE
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 22,680
- Exercise price
- $10.71
- Footnotes
- F1
NGNE
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,352
- Exercise price
- $23.02
- Footnotes
- F2
NGNE
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 22,680
- Exercise price
- $18.39
- Footnotes
- F3
NGNE
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,514
- Exercise price
- $5.82
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
This option represents a right to purchase 22,680 shares of the Issuer's common stock. 25% of this option vested on October 7, 2021, with the remainder vesting in equal monthly installments through October 7, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Footnote F2
This option represents a right to purchase 15,352 shares of the Issuer's common stock. 25% of this option vested on September 23, 2022, with the remainder vesting in equal monthly installments through September 23, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Footnote F3
This option represents a right to purchase 22,680 shares of the Issuer's common stock. 25% of this option will vest on March 9, 2024, with the remainder vesting in equal monthly installments through March 9, 2027, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Footnote F4
This option represents a right to purchase 13,514 shares of the Issuer's common stock and is fully vested.
SEC remarks
Exhibit 24 - Power of Attorney